Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1912399-75-7

Post Buying Request

1912399-75-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1912399-75-7 Usage

General Description

BT11 is a genetically modified crop developed by Syngenta that is resistant to pests, specifically the European corn borer. The crop contains a protein called Cry1Ab, which is derived from the bacterium Bacillus thuringiensis. When the European corn borer larvae ingest the BT11 crop, the Cry1Ab protein binds to receptors in the larvae's gut, causing the gut lining to break down and ultimately leading to the insect's death. This resistance to pests allows for reduced reliance on chemical insecticides, which can be beneficial for both the environment and crop yields. BT11 has been approved for commercial use in various countries including the United States and Canada.

Check Digit Verification of cas no

The CAS Registry Mumber 1912399-75-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,9,1,2,3,9 and 9 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1912399-75:
(9*1)+(8*9)+(7*1)+(6*2)+(5*3)+(4*9)+(3*9)+(2*7)+(1*5)=197
197 % 10 = 7
So 1912399-75-7 is a valid CAS Registry Number.

1912399-75-7Downstream Products

1912399-75-7Relevant articles and documents

An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease

Carbo, Adria,Gandour, Richard D.,Hontecillas, Raquel,Philipson, Noah,Uren, Aykut,Bassaganya-Riera, Josep

, p. 10113 - 10126 (2016)

Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects. This study reports the first LANCL2-based therapeutics for inflammatory bowel disease (IBD). Analogues of 1 (ABA) and 2 (NSC61610) were screened by molecular docking, then synthesized and analyzed for binding to LANCL2 by surface plasmon resonance. Piperazine-1,4-diylbis(6-benzo[d]imidazole-2-yl)pyridine-2-yl)methanone, 7, was identified as the lead LANCL2-binding compound for treating IBD. The oral treatment with 7 (8 mg/kg/d) in a mouse model of IBD resulted in lowering the disease activity index, decreasing colonic inflammatory lesions by 4-fold, and suppressing inflammatory markers (e.g., TNF-α, and interferon-γ) in the gut. Furthermore, studies in LANCL2-/- mice demonstrated that loss of LANCL2 abrogated beneficial actions of 7, suggesting high selectivity for the target. In conclusion, 7 merits continued development as a LANCL2-based, first-in-class orally active therapeutic for IBD.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1912399-75-7